Regulations.gov document
Determination That VISTARIL (Hydroxyzine Pamoate) Oral Suspension, 25 Milligrams/5…
Notice · FDA-2023-P-5095 · posted Apr 11, 2024
Key facts
| Document ID | FDA-2023-P-5095-0003 |
|---|---|
| Title | Determination That VISTARIL (Hydroxyzine Pamoate) Oral Suspension, 25 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2023-P-5095 |
| Posted | Apr 11, 2024 |
| Federal Register citation | 89 FR 25631 |
| FR document number | 2024-07707 |
| Comment period opens | Apr 11, 2024 |
| Effective date | Apr 11, 2024 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: